Baidu
map

医药商业企业四大转型方向(上篇)

2017-04-27 医药史立臣 医药商业企业四大转型方向(上篇)

国家的政策导向下,我国的医药商业各种要素会进行碎片化分解,随着分解,各种商业要素会向专业化方向发展。

我国的医药商业企业大致分为十种类型(不包括药材商):1.代理销售商:代理药企的产品为主,核心区域有自己的销售队伍,有终端资源,也通过招商模式拓展非核心区域市场。2.代理招商型:代理药企的产品为主,没是队伍,通过对代理区域的市场招商完成销售,没有终端资源,几乎无市场掌控能力。3.区域配送商:区域内招标、基药等政府、医院、医联体指定配送商业,配送这些指定产品毛利低,也会配送外部产品,毛利稍高。没有专业的销售团队,与自然人合作较多,区域性质明显,发展潜力很小。4.流通调拨商:以大流通普药品种为主,纵向层层调拨,横向跨区域调拨,业务量大,毛利低,有较为完善的配送体系,资金回笼有风险。5.经销商:所在区域有销售队伍,大部分区域没有销售队伍,主要是为制药企业解决物流、资金和招标等问题,通过自身的配送系统向下级商业配送,提前垫付产品资金。有较强的资金实力和配送能力,但销售功能较弱,6.过票挂靠商:依靠医药个代过票和挂靠为主,依托税利的差额盈利,无销售队伍,无终端资源。7.医院纯销商:区域内有较好的医院终端资源,主要围绕招标、二次议价后的产品,帮助制药企业进入医院,有自己的临床销售队伍,主要是小包为主

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771731, encodeId=05561e71731eb, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Fri May 05 18:39:00 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408900, encodeId=5e7f14089004d, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456069, encodeId=834c14560697b, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535034, encodeId=2ab2153503494, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1771731, encodeId=05561e71731eb, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Fri May 05 18:39:00 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408900, encodeId=5e7f14089004d, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456069, encodeId=834c14560697b, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535034, encodeId=2ab2153503494, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-04-29 cathymary
  3. [GetPortalCommentsPageByObjectIdResponse(id=1771731, encodeId=05561e71731eb, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Fri May 05 18:39:00 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408900, encodeId=5e7f14089004d, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456069, encodeId=834c14560697b, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535034, encodeId=2ab2153503494, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-04-29 hyf030
  4. [GetPortalCommentsPageByObjectIdResponse(id=1771731, encodeId=05561e71731eb, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Fri May 05 18:39:00 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408900, encodeId=5e7f14089004d, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456069, encodeId=834c14560697b, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535034, encodeId=2ab2153503494, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Apr 29 04:39:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]

相关资讯

原创:医生眼中的

七一从文,医学博士,为您讲述医疗故事,与您分享从医经历。

美国三大医药商业企业的启示

美国这三大医药商业企业,占据了大约90%的美国医药商业份额。这三个商业企业之所以能够在诸多的医药商业企业竞争中存活,主要是其业态并不单纯是配送批发,而是向上下游延伸,构建了较为全面的增值服务体系

原创:莆田系妇科、男科医院难以名状的罪恶

七一从文,医学博士,为您讲述医疗故事,与您分享从医经历。

我们把美丽好的青春奉献给了陌生人

我二十五岁从中山医科大学毕业,开始工作,到现在,已经17年了,十几年的时光,一眨眼,就过去了。

现代阿Q

我有一个朋友,我叫他阿Q。

Baidu
map
Baidu
map
Baidu
map